Skip to content
Search

Latest Stories

MHRA recalls Clexane 4,000 IU 40mg syringes 

The Medicines and Health products Regulatory Agency (MHRA) has issued a class second medicines recall for Clexane 4,000 IU (40mg) /0.4ml syringes  of Pharmaram Ltd.

Pharmaram has informed the MHRA that the batch of Clexane 4,000IU (40mg)/0.4ml syringes has an error on the labelling affixed to the plastic blister packaging encasing the syringe.


Product details

Batch NumberExpiry DatePack Size First Distributed
CCL67G/D331/10/202210 syringes per pack16/07/2020

The label incorrectly states “Clexane 6,000IU (60mg)/0.6ml Syringes”, when it should have stated “Clexane 4,000IU (40mg)/0.4ml Syringes”.

The outer carton states the correct strength; the batch number and expiry dates are also correct and match the details on the labelling.

Healthcare professionals have been adviced to stop supplying the products immediately and remove from the shelves within their pharmacies.

Patients who have been supplied this batch of Clexane 4,000IU (40mg)/0.4ml Syringes should be informed that the error is only with the labelling on the plastic blister packaging encasing the syringe.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less